aplitabart + docetaxel + gemcitabine

Aplitabart + docetaxel + gemcitabine is an experimental combination therapy comprising three antineoplastic agents: - **Aplitabart** (IGM-8444), a human IgM monoclonal antibody that acts as a multivalent agonist of *tumor necrosis factor-related apoptosis-inducing ligand receptor 2* (TRAIL receptor 2, DR5), inducing apoptosis in cancer cells, developed by IGM Biosciences[1][3][7]. - **Docetaxel**, a taxane-class cytotoxic chemotherapeutic that stabilizes microtubules, inhibiting cell division. - **Gemcitabine**, a nucleoside analog that impedes DNA synthesis and repair, leading to cell cycle arrest and apoptosis. This regimen is being investigated for refractory or relapsed solid tumors and hematological malignancies, with early-phase development and combination therapy exploratory status as of 2025. The mechanistic rationale relies on synergistic apoptosis via intrinsic (gemcitabine, docetaxel) and extrinsic (aplitabart-mediated DR5 activation) pathways[1][3][9].